PubRank

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?

PubWeight™: 0.75‹?›

🔗 View Article (PMID 32303915)

Published in Drug Saf on May 22, 2020

Authors

Gianluca Trifirò1, Salvatore Crisafulli2, Giuseppe Andò3, Giorgio Racagni4, Filippo Drago5, Italian Society of Pharmacology

Author Affiliations

1: Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. trifirog@unime.it.
2: Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
3: Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
4: Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
5: Department of Biomedical and Biotechnological Sciences, Clinical Pharmacology Unit of the University Hospital, University of Catania, Catania, Italy.

Articles cited by this ↗

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med (2020) 7.12

Articles by these authors ⇆

New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials. Expert Rev Cardiovasc Ther (2015) 0.82

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. Int J Cardiol (2016) 0.75

Cardiovascular outcomes and conventional risk factors in non-diabetic adult patients with GH deficiency: A long-term retrospective cohort study. Eur J Intern Med (2015) 0.75

The antiviral and immunomodulatory activities of propolis: An update and future perspectives for respiratory diseases. Med Res Rev (2021) 0.75